Skip to main content

The context you need, when you need it

When news breaks, you need to understand what actually matters — and what to do about it. At Vox, our mission to help you make sense of the world has never been more vital. But we can’t do it on our own.

We rely on readers like you to fund our journalism. Will you support our work and become a Vox Member today?

Join now

Lew Cirne’s New Relic Just Raised Another $100 Million

Lead investors are BlackRock and Passport Capital.

New Relic

Add another $100 million to the steadily growing pile of money being thrown at the software startup New Relic.

The company just announced that it had secured a Series F funding round led by investment firms BlackRock and Passport Capital, with T. Rowe Price and Wellington Management also participating. The round brings the total capital raised at New Relic to $215 million.

Update: I’ve just talked to a source familiar with the terms of the deal who tells Re/code that the deal values New Relic at between $1.2 billion and $1.3 billion.

New Relic — the name is an anagram of the name of CEO Lew Cirne — is a cloud-based application that monitors software for what goes on inside it. Companies use it to figure out what’s going wrong with an application, but have also found it useful to understand the second-by-second click-stream data of Web applications. That has turned into a thoughtful pivot in the direction of analytics, which so many companies consider important in this new age of “Big Data.”

The company also got a big shot in the arm when its name appeared in a report documenting how the Obama administration started turning the tide with the problem-plagued launch of the Healthcare.gov website last year. While the company can’t talk about it, its role in the fix is considered a bit of an open secret that has gone a long way toward helping its reputation.

New Relic’s previous investors include Allen & Company, Benchmark, Dragoneer Investment Group, Insight Venture Partners, Tenaya Capital and Trinity Ventures.

The addition of T. Rowe Price to the stable of investors makes it look like New Relic is starting to rev the engines for an IPO. Its investment in Workday and Facebook were considered strong signals that an IPO was not far in the future.

About that: Cirne will always demur if you ask him about it. But the company has been beefing up its management team and board. In December it lured Hilarie Koplow-McAdams away from Salesforce.com to be its chief revenue officer. It also added Square CFO Sarah Friar to its board in January, and before that it tapped longtime Silicon Valley finance guru Peter Currie for another board seat. After six rounds of funding, it won’t be long now.

This article originally appeared on Recode.net.

More in Technology

Podcasts
Are humanoid robots all hype?Are humanoid robots all hype?
Podcast
Podcasts

AI is making them better — but they’re not going to be doing your chores anytime soon.

By Avishay Artsy and Sean Rameswaram
Future Perfect
The old tech that could help stop the next airborne pandemicThe old tech that could help stop the next airborne pandemic
Future Perfect

Glycol vapors, explained.

By Shayna Korol
Future Perfect
Elon Musk could lose his case against OpenAI — and still get what he wantsElon Musk could lose his case against OpenAI — and still get what he wants
Future Perfect

It’s not about who wins. It’s about the dirty laundry you air along the way.

By Sara Herschander
Life
Why banning kids from AI isn’t the answerWhy banning kids from AI isn’t the answer
Life

What kids really need in the age of artificial intelligence.

By Anna North
Culture
Anthropic owes authors $1.5B for pirating work — but the claims process is a Kafkaesque messAnthropic owes authors $1.5B for pirating work — but the claims process is a Kafkaesque mess
Culture

“Your AI monster ate all our work. Now you’re trying to pay us off with this piece of garbage that doesn’t work.”

By Constance Grady
Future Perfect
Some deaf children are hearing again because of a new gene therapySome deaf children are hearing again because of a new gene therapy
Future Perfect

A medical field that almost died is quietly fixing one disease at a time.

By Bryan Walsh